ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: ICU Medical is a leader in developing, manufacturing, and selling proprietary disposable medical connection systems for vascular therapy, primarily designed to prevent needlesticks and bloodstream infections. The company's core product is the CLAVE needleless connector. In May 2005, the company acquired Hospira, Inc.'s Salt Lake City manufacturing facility and entered a 20-year Manufacturing, Commercialization and Distribution Agreement (MCDA) to produce critical care devices (catheters, angiography kits) exclusively for Hospira.

Key Financial Metrics (Year Ended Dec 31, 2006)

Debt and Liquidity: The company reported no long-term debt in the balance sheet summary. Current liabilities totaled $15.9 million. The company maintains a strong liquidity position with $116.9 million in cash and liquid investments.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 28% to $201.6 million, driven primarily by a 29% increase in sales to Hospira ($148.4 million in 2006 vs. $115.0 million in 2005). This includes $75.8 million in sales under the MCDA (critical care products).
• Margin Compression: Gross margin declined from 44% in 2005 to 40% in 2006. Management attributed this to approximately $8.6 million in non-recurring costs and inefficiencies, including:
  • Costs associated with moving production from San Clemente to Salt Lake City ($3.0 million impact).
  • Production inefficiencies in Mexico due to rapid workforce expansion and training ($2.1 million impact).
  • Charges related to the discontinuation of Punctur-Guard products ($0.7 million).
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased to $44.2 million (22% of revenue) from $37.0 million (23% of revenue). This included $6.4 million in legal expenses related to patent litigation and a lawsuit against a law firm (settled in Jan 2007 for $8 million).
• Other Income: Increased to $4.5 million, driven by higher interest income ($3.7 million) and a settlement payment ($0.8 million).

Guidance, Outlook, and Risks

• 2007 Outlook: Management expects gross margins to recover to approximately 43-44% in 2007 as production inefficiencies are resolved by the second quarter. SG&A is expected to be 21-23% of revenue, and R&D is expected to be 4-5% of revenue.
• Customer Concentration Risk: Hospira remains the dominant customer, accounting for 77% of total revenue in 2006. The company's financial performance is heavily dependent on the success of the MCDA and Hospira's market position.
• Legal Proceedings:
  • Patent Litigation: The company is involved in patent infringement litigation against Alaris (Cardinal Health). A court ruling in early 2007 granted summary judgment of invalidity on certain claims, which the company intends to appeal.
  • Law Firm Settlement: Settled a lawsuit against former attorneys for $8 million in January 2007.
  • Medegen Claim: Defending against a patent infringement claim filed in July 2006 regarding CLC2000 and TEGO products; management believes there is no significant financial exposure.
• Operational Risks: Risks include the ability to reduce manufacturing costs under the MCDA, integration of new products, and potential disruption in Mexico operations due to labor turnover or border issues.

Key Facts for Investor Verification

• Hospira Dependency: Verify the stability of the 20-year MCDA and Hospira's market share, as 77% of revenue is derived from this single customer.
• Margin Recovery: Monitor Q1 and Q2 2007 results to confirm the resolution of production inefficiencies in Mexico and Salt Lake City and the return of gross margins to the 43-44% range.
• Legal Outcomes: Track the appeal of the patent invalidity ruling against Alaris and the status of the Medegen infringement claim, as these could impact future CLAVE and CLC2000 sales.
• Capital Allocation: The company has a stock repurchase program (expanded to $20 million in Jan 2007) and significant capital expenditures planned for 2007 (approx. $20 million) for facility expansions.
• Product Mix Shift: Observe the growth of critical care products (38% of revenue) versus traditional CLAVE products (34% of revenue) to assess the success of the diversification strategy.